Scott Miles, MD
Addiction Medicine · St.mary's, GANPI 1073512125
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 38 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 14 manufacturers, the largest accounting for just 20.8% — the pattern of someone who eats at a lot of different presentations. 2025 is the largest year on record at $709, more than ten times the $18 reported in 2019.
Across 38 payments — averaging $23.33 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Collegium Pharmaceutical, Inc.$185
- Braeburn Inc.$127
- Indivior Inc.$108
- Medtronic$74
- Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$59
- Vertex$52
- plus $282 from 8 others
What the payments were for
- Food & beverage$887100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Collegium Pharmaceutical, Inc. | 10 | $185 |
| Braeburn Inc. | 5 | $127 |
| Indivior Inc. | 5 | $108 |
| Medtronic | 1 | $74 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 3 | $59 |
| Vertex | 2 | $52 |
| AbbVie | 3 | $48 |
| Boston Scientific | 1 | $48 |
| Orexo US, Inc. | 2 | $41 |
| Valinor Pharma, LLC | 2 | $41 |
| Solventum Corporation | 1 | $34 |
| Globus Medical | 1 | $32 |
| Protega Pharmaceutials Inc | 1 | $23 |
| Forte Bio-pharma LLC | 1 | $15 |
How this compares
$887 in reported general payments places this provider in the 85th percentile of 35 addiction medicine providers in Georgia.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| BelbucaBuprenorphine Hcl | 70 | $54,825 |
| RelistorMethylnaltrexone Bromide | 17 | $44,123 |
| Nurtec OdtRimegepant Sulfate | 15 | $34,211 |
| UbrelvyUbrogepant | 14 | $27,067 |
| Buprenorphine-NaloxoneBuprenorphine Hcl/Naloxone Hcl | 159 | $21,215 |
| Buprenorphine | 85 | $18,839 |
| Oxycodone-AcetaminophenOxycodone Hcl/Acetaminophen | 441 | $18,538 |
| Hydrocodone-AcetaminophenHydrocodone/Acetaminophen | 329 | $12,556 |
| Xtampza ErOxycodone Myristate | 21 | $10,603 |
| OxycontinOxycodone Hcl | 21 | $9,360 |
| MovantikNaloxegol Oxalate | 14 | $5,755 |
| Oxycodone Hcl | 258 | $4,580 |
| Lidocaine | 24 | $4,498 |
| Pregabalin | 173 | $4,086 |
| Tizanidine Hcl | 145 | $2,684 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Collegium Pharmaceutical, Inc.Belbuca, Xtampza Er | $185 | $65,42891 claims |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLCRelistor | $59 | $44,12317 claims |
| AbbVieUbrelvy | $48 | $27,06714 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 35 addiction medicine providers in Georgia.
Other addiction medicine in St.mary's
- Kimberlynn RichardsSmyrna$14K
- Tommie RichardsonSmyrna$14K
- Derek KlemmDemorest$5K
- Daniel GolightlySmyrna$2K
- Roy AryAtlanta$749
- Ajibola BabatundeAcworth$549
- Patrice MarshallDecatur$453
- Stacy SeikelDahlonega$414
- Claire TuckerStatesboro$352
- Sabrina HannaDahlonega$271
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.